TrialNeurological research and practice2019

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response.

Laura Bierhansl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.